NF-κB Activation Inhibitor

A cell-permeable quinazoline compound that acts as a potent inhibitor of NF-κB transcriptional activation (IC₅₀ = 11 nM in Jurkat cells) and LPS-induced TNF-α production (IC₅₀ = 7 nM in murine splenocytes). Does not exhibit cellular cytotoxicity even at concentrations as high as 10 µM. Reported to exhibit anti-inflammatory effects on carregeenin-induced paw edema in rats.

Cell permeable: yes

Primary Target
NF-κB transcriptional activation

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 11 nM against NF-κB transcriptional activation in Jurkat cells; 7 nM against LPS-induced TNF-α production in murine splenocytes

Packaged under inert gas

Toxicity: Toxic (F)

A 10 mM (1 mg/281 µl) solution of NF-κB Activation Inhibitor (Cat. No. 481406) in DMSO.

Following initial use, aliquot and refrigerate (4°C).

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Tobe, M., et al. 2003. Bioorg. Med. Chem.11, 383.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany